OBJECTIVES: Patients treated with maraviroc frequently show high CD4+ T cell increases. The aim of this study was to detail the characteristics of maraviroc-induced immune recovery. PATIENTS AND METHODS: We studied T cell subsets from frozen peripheral blood mononuclear cells of patients treated with raltegravir, etravirine and either maraviroc (REM, n = 24) or darunavir/ritonavir (RED, n = 17). RESULTS: The two groups showed a similar decrease in activated CD4+ and CD8+ T cells. A greater loss of naive CD4+ T cells and a reduction in cells expressing CXCR4 were observed in REM patients, while RED patients showed a greater loss of cells expressing CCR5. CONCLUSIONS: Our findings do not support a role for reduction in activated T cell subsets to explain the greater maraviroc-induced immune recovery. Reduction in CXCR4+CD4+ and higher expression of CCR5+CD4+ T cells might represent a potential protection from non-R5 tropic viral strain overgrowth.
OBJECTIVES:Patients treated with maraviroc frequently show high CD4+ T cell increases. The aim of this study was to detail the characteristics of maraviroc-induced immune recovery. PATIENTS AND METHODS: We studied T cell subsets from frozen peripheral blood mononuclear cells of patients treated with raltegravir, etravirine and either maraviroc (REM, n = 24) or darunavir/ritonavir (RED, n = 17). RESULTS: The two groups showed a similar decrease in activated CD4+ and CD8+ T cells. A greater loss of naive CD4+ T cells and a reduction in cells expressing CXCR4 were observed in REM patients, while REDpatients showed a greater loss of cells expressing CCR5. CONCLUSIONS: Our findings do not support a role for reduction in activated T cell subsets to explain the greater maraviroc-induced immune recovery. Reduction in CXCR4+CD4+ and higher expression of CCR5+CD4+ T cells might represent a potential protection from non-R5 tropic viral strain overgrowth.
Authors: Nadejda Beliakova-Bethell; Sonia Jain; Christopher H Woelk; Mallory D Witt; Xiaoying Sun; Steven M Lada; Celsa A Spina; Miguel Goicoechea; Steffney E Rought; Richard Haubrich; Michael P Dubé Journal: Antiviral Res Date: 2014-04-24 Impact factor: 5.970
Authors: Ai Kawana-Tachikawa; Josep M Llibre; Isabel Bravo; Roser Escrig; Beatriz Mothe; Jordi Puig; Maria C Puertas; Javier Martinez-Picado; Julia Blanco; Christian Manzardo; Jose M Miro; Aikichi Iwamoto; Anton L Pozniak; Jose M Gatell; Bonaventura Clotet; Christian Brander Journal: PLoS One Date: 2014-01-27 Impact factor: 3.240